Theravance Biopharma price target raised to $25 by BTIG on China approval

BTIG raised its price target on Theravance Biopharma (TBPH) to $25 from $24, maintaining a Buy rating, following the China approval of Yupelri. This approval triggers a $7.5 million milestone payment and establishes future tiered royalties from Viatris, which will handle commercialization in the substantial Chinese COPD market at no cost to Theravance. This strategic gain, alongside the recent $225 million sale of future Trelegy royalties and the company's strong financial health, underpins analyst expectations for TBPH to achieve profitability in 2025, despite a recent Q1 EPS miss.

Analysis

Theravance Biopharma (TBPH) has secured a significant strategic win with the approval of Yupelri in China, prompting BTIG to raise its price target to $25.00. This approval immediately de-risks the asset, with BTIG adjusting its probability of success to 100%, and triggers a $7.5 million milestone payment expected in Q3 2025. The commercial arrangement with Viatris is highly favorable, as Theravance will incur no commercialization costs while being eligible for up to $37.5 million in sales-based milestones and 14-20% tiered royalties. The market potential is substantial, targeting China's estimated 100 million COPD patients, with Viatris providing a robust commercial infrastructure of 4,200 sales representatives. This development complements the company's recently strengthened balance sheet, which includes a strong cash position relative to debt and a $225 million cash infusion from the sale of future Trelegy royalties to GSK. While the company reported a Q1 EPS miss at -$0.27, revenue slightly beat expectations at $15.4 million, a 6% year-over-year increase, and analysts project a pivotal turn to profitability in 2025. Despite a recent 25.8% stock return and a positive analyst outlook, it is noteworthy that InvestingPro's analysis suggests the stock is currently overvalued. Future catalysts are centered on the CYPRESS study, with enrollment completion expected in late summer 2025 and data disclosure in H1 2026.

Key Decisions for Investors

• Investors should view the Yupelri approval in China as a key de-risking event that provides a clear, cost-free path to a significant new revenue stream, supporting the analyst consensus for profitability in 2025.
• It is crucial to monitor the execution of the Viatris partnership and the initial sales ramp-up of Yupelri in China, as this will be the primary driver for realizing the projected royalties and sales milestones.
• While analyst targets suggest considerable upside, investors should weigh this against the stock's 25.8% run-up over the past year and the conflicting signal from InvestingPro suggesting it is overvalued, while also keeping an eye on the next major clinical catalyst, the CYPRESS study data expected in H1 2026.